Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: A diagnostic pitfall

American Journal of Surgical Pathology

Volumn 38, Issue 7, 2014, Pages 941-945

  Gordetsky, Jennifer ^a   Epstein, Jonathan I ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Gleason grading; prostate adenocarcinoma; pseudopapillary

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BIOPSY; BLADDER TUMOR; CANCER GRADING; CELL PROLIFERATION; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NECROSIS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; UROTHELIUM;

ADENOCARCINOMA, PAPILLARY; AGED; BIOPSY; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NECROSIS; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84902549858     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000178     Document Type: Article

References (19)

1. Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol. 1977;118: 399-403.
2. Chibber PJ, McIntyre MA, Hindmarsh JR, et al. Transitional cell carcinoma involving the prostate. Br J Urol. 1981;53: 605-609.
3. Knoedler JJ, Boorjian SA, Tollefson MK, et al. Urothelialcarcinoma involving the prostate: the association of revised tumor stage and coexistent bladder cancer with survival following radical cystectomy. BJU Int. 2013. doi: 10.1111/bju.12486. [Epub ahead of print].
4. Patel AR, Cohn JA, Abd El Latif A, et al. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma. J Urol. 2013;189: 53-58.
5. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36: 1472-1476.
6. Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol. 2012;43: 313-324.
7. Bruins HM, Djaladat H, Ahmadi H, et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1, 476 radical cystoprostatectomy specimens. J Urol. 2013;190: 1704-1709.
8. Calonje E, Fletcher CD. Sinusoidal hemangioma. A distinctive benign vascular neoplasm within the group of cavernous hemangiomas. Am J Surg Pathol. 1991;15: 1130-1135.
9. Ates D, Kosemehmetoglu K, Onder S, et al. Pseudopapillary pattern in intra-operative squash smear preparations of central nervous system germinomas. Cytopathology. 2013;1: 45-50.
10. Ribu DL, Shield PW, Bligh JF. The varied presentation of metastatic melanoma in fine needle aspiration cytology of the breast. Cytopathology. 2012;23: 256-262.
11. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31: 1246-1255.
12. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27: 1-10.
13. Giannico GA, Ross HM, Lotan T, et al. Aberrant expression of p63 in adenocarcinoma of the prostate: a radical prostatectomy study. Am J Surg Pathol. 2013;37: 1401-1406.
14. Osunkoya AO, Hansel DE, Sun X, et al. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008;32: 461-467.
15. Bassily NH, Vallorosi CJ, Akdas G, et al. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol. 2000;113: 383-388.
16. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33: 1136-1140.
17. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113: 683-687.
18. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2013;1: 13-22.
19. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50: 472-483.